During the past decade, Masarykuv onkologicky ustav conducted 46 clinical trials. In the 10-year time frame, 46 clinical trials started and 34 clinical trials were completed, i.e. on average, 73.9% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 20 clinical trials were completed. i.e. 111.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Masarykuv onkologicky ustav" #1 sponsor was "Hoffmann-La Roche" with 17 trials, followed by "Pfizer" with 8 trials sponsored, "Eisai Inc." with 3 trials sponsored, "Eli Lilly and Company" with 3 trials sponsored and "Genentech, Inc." with 3 trials sponsored. Other sponsors include 32 different institutions and companies that sponsored additional 34 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Masarykuv onkologicky ustav" #1 collaborator was "Merck Sharp & Dohme LLC" with 3 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "Alleanza Contro il Cancro" with 1 trials as a collaborator and "Anticancer Fund, Belgium" with 1 trials as a collaborator. Other collaborators include 22 different institutions and companies that were collaborators in the rest 32 trials.

According to Clinical.Site data, the most researched conditions in "Masarykuv onkologicky ustav" are "Breast Cancer" (8 trials), "Renal Cell Carcinoma" (5 trials), "Colorectal Cancer" (3 trials), "Gastric Cancer" (3 trials) and "Ovarian Cancer" (3 trials). Many other conditions were trialed in "Masarykuv onkologicky ustav" in a lesser frequency.

Most popular intervention types in "Masarykuv onkologicky ustav" are "Drug" (64 trials), "Other" (9 trials), "Procedure" (5 trials), "Biological" (4 trials) and "Radiation" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "Atezolizumab" (11 trials), "Paclitaxel" (9 trials), "Bevacizumab" (6 trials) and "Docetaxel" (6 trials). Other intervention names were less common.

The vast majority of trials in "Masarykuv onkologicky ustav" are 54 trials for "All" genders, 12 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are NaN active trials in "Masarykuv onkologicky ustav". undefined are not yet recruiting, 15 are recruiting, 15 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 36 completed trials in Masarykuv onkologicky ustav, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Masarykuv onkologicky ustav, 3 "Phase 1" clinical trials were conducted, 19 "Phase 2" clinical trials and 43 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 5 trials that are defined as “Not Applicable".

Masarykuv onkologicky ustav has several departments that took part in Clinical trials: "Masarykův onkologický ústav; Klinika komplexní onkologické péče" - 14 trials